Serono was a biotechnology company headquartered in Geneva , Switzerland . It was acquired by the German pharmaceutical company Merck in 2006. The company was founded as the Serono Pharmacological Institute by Cesare Serono in 1906 in Rome , Italy . A key step in its development was the discovery of a method of extracting urinary gonadotropins by Dr. Piero Donini. Serono was incorporated in 1987 and the holding company, Ares-Serono S.A., changed its name to Serono S.A. in May 2000.
10-471: Manteia Predictive Medicine S.A. (initially incorporated under the name "GenInEx S.A.") was a start-up company created in November 2000 as a spin-off of Serono , a Swiss-based biotechnology company, now part of Merck-Serono, by private founders. Its aim was to provide preventive and curative treatment guidelines for common and complex diseases. These guidelines were envisaged as composed of two parts: The company
20-539: Is called Merck Serono . Its headquarters was in Geneva, within the new Serono facilities. The US operations remain near Boston and was renamed here EMD Serono due to trademark issues with Merck & Co./MSD . The process of merging started in January 2007 after various business regulatory reviews and phases were complete. Until that time, Serono and Merck KGaA operated as separate entities. The new, combined entity, Merck Serono
30-523: Is the size of other large biotechs. In 2011, a decision was made to close the Geneva headquarters and move the headquarters to Darmstadt, Germany resulting in job losses to most of the employees in Geneva. Serono operated in 44 countries, with manufacturing facilities in eight countries and sales in over 90 countries. Main manufacturing sites were in Switzerland, Italy, Spain and France; a fifth facility in Israel
40-462: The Geneva research site moved to a brand new campus (Horizon Secheron) in the heart of Geneva in 2006. This facility and the headquarters were closed by Merck KGaA in 2013. The building was sold back to Bertarelli family. In 2005, Serono agreed to a $ 704 million settlement with the Department of Justice to resolve civil and criminal allegations that the company engaged in a fraudulent scheme to promote
50-560: The acquisition in 1997 of GBRI from GlaxoWelcome, becoming its Geneva based research institute named SPRI, and the Manteia Predictive Medicine spin-off, Serono also nursed the emergence of now a commercial leading massive parallel sequencing technology. 36% of Serono was sold to Merck KGaA in Sept. 2006 for €10.6 billion; Merck KGaA paid CHF 1,100 for each share. The new entity, which merges Serono with Merck's Ethicals division,
60-493: The drug Serostim for off-label uses and paid out illegal kickbacks for prescribing the drug in violation of the False Claims Act . The settlement is, to date, the ninth largest pharmaceutical settlement in U.S. history. Serono provides Fertility LifeLines as a free and confidential source of information to infertility patients. United States Department of Justice Too Many Requests If you report this error to
70-643: The fields of reproductive health , multiple sclerosis , growth & metabolism and dermatology . The eight biotechnology products are available in four core therapeutic areas: neurology for the treatment of relapsing forms of multiple sclerosis , reproductive health for treatments of infertility , dermatology , where Serono has launched biologics in Europe for moderate-to-severe psoriasis , and growth and metabolism for treatments for HIV-associated wasting and growth deficiencies. The company also conducts research in oncology and autoimmune diseases . Through
80-430: Was basing its strategy on the development of so-called "DNA colony sequencing" technology (now commercialized by Illumina ), its proprietary massive parallel sequencing technology whose development had been initiated in late 1996 at Glaxo-Welcome's Geneva Biomedical Research Institute (GBRI), by Pascal Mayer and Laurent Farinelli. This work has been protected by several patents and patents applications, publications and
90-457: Was closed in 2004 owing to its obsolescence. Research and development facilities were maintained in Geneva, Switzerland , Boston, USA , and Ivrea , Italy. It employed over 4,750 people with worldwide revenues of USD 2,586.4 million (2005). It had eight biotechnology products on the market, and more than 25 ongoing preclinical and clinical development projects at the end of 2005. Serono Headquarters and
100-506: Was discussed in presentations at international conferences from 1998 to 2001. By the end of 2003, while the company was progressing along its plans towards realizing an industrial instrument capable of sequencing a complete human genome in approximately 24 hours, strategic considerations led the main shareholder ( Serono ) to sell Manteia's colony DNA sequencing technology to UK based Solexa Ltd, now part of Illumina (company) . Serono Serono develops and markets pharmaceuticals in
#512487